Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 4/20 | 0.37 |
| ▸ | PLAU | P00749 | 3/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15321837 | 1.00 | ACHE (0.40) | ACHEALDH1A1HSD17B10PDK4ELANE | |
| SCHEMBL16584237 | 0.81 | KDM4E (0.38) | ACHEALDH1A1ELANEPLAUF2 | |
| SCHEMBL16584238 | 0.81 | KDM4E (0.38) | ACHEALDH1A1ELANEPLAUF2 | |
| SCHEMBL10572662 | 0.80 | LMNA (0.45) | ACHEHSD17B10ELANEPLAUF2 | |
| SCHEMBL15601821 | 0.79 | ALDH1A1 (0.44) | ACHEALDH1A1PDK4KDM4E | |
| SCHEMBL29427432 | 0.78 | KDM4E (0.43) | ACHEALDH1A1ELANEKDM4E | |
| SCHEMBL30697624 | 0.78 | ALDH1A1 (0.40) | ACHEALDH1A1PDK4ELANEPLAU | |
| SCHEMBL22531284 | 0.78 | ALDH1A1 (0.40) | ACHEALDH1A1PDK4KDM4E | |
| SCHEMBL22531282 | 0.78 | ALDH1A1 (0.40) | ACHEALDH1A1PDK4KDM4E | |
| SCHEMBL15592115 | 0.78 | ALDH1A1 (0.40) | ACHEALDH1A1PDK4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964636-B | Triazolopyrimidines method for synthesizing compound | 上海陶术生物科技股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-117964636-A | Synthesis method of triazolopyrimidine compound | 上海陶术生物科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| US-20250367143-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367158-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4543857-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA Pharmaceuticals Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-117964636-B | Triazolopyrimidines method for synthesizing compound | 上海陶术生物科技股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-117964636-A | Synthesis method of triazolopyrimidine compound | 上海陶术生物科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023250060-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2022064453-A1 | NEMATOCIDAL COMPOUNDS AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-31 | — | — | WO | disclosed |
| EP-2834238-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9296745-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2834238-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | Pfizer Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| CN-104334557-A | Diacylglycerol acyltransferase 2 inhibitors | PFIZER | 2015-02-04 | — | — | CN | disclosed |
| WO-2013150416-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367143-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR84, GPR68 | ACHE 812/4885ALDH1A1 2684/4885HSD17B10 1851/4885 |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, PLAAT2 | ACHE 3136/4885ALDH1A1 453/4885HSD17B10 627/4885 |
| US-20250367158-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR68, HTR2A | ACHE 711/4885ALDH1A1 2000/4885HSD17B10 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.